Similar articles for PMID: 25342386

Year	Number of Results
1969	1
1995	1
2000	1
2002	1
2003	1
2005	2
2006	1
2007	1
2008	2
2009	3
2010	4
2011	3
2012	10
2013	10
2014	16
2015	15
2016	14
2017	11
2018	15
2019	6
2020	7
2021	7
2022	3
2023	0

1

Can PET/CT guide the personalized treatment of patients with gastroenteropancreatic neuroendocrine neoplasms?

Schillaci O. Schillaci O. J Nucl Med. 2014 Nov;55(11):1757-8. doi: 10.2967/jnumed.114.147538. Epub 2014 Oct 23. J Nucl Med. 2014. PMID: 25342386 Free article. No abstract available.

2

Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?

Has Simsek D, Kuyumcu S, Turkmen C, Sanlı Y, Aykan F, Unal S, Adalet I. Has Simsek D, et al. J Nucl Med. 2014 Nov;55(11):1811-7. doi: 10.2967/jnumed.114.142224. Epub 2014 Oct 14. J Nucl Med. 2014. PMID: 25315243 Free article.

3

Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?

Naswa N, Sharma P, Gupta SK, Karunanithi S, Reddy RM, Patnecha M, Lata S, Kumar R, Malhotra A, Bal C. Naswa N, et al. Clin Nucl Med. 2014 Jan;39(1):e27-34. doi: 10.1097/RLU.0b013e31827a216b. Clin Nucl Med. 2014. PMID: 24217539

4

Hepatocellular carcinoma and gastroenteropancreatic neuroendocrine tumors: potential role of other positron emission tomography radiotracers.

Jadvar H. Jadvar H. Semin Nucl Med. 2012 Jul;42(4):247-54. doi: 10.1053/j.semnuclmed.2012.02.001. Semin Nucl Med. 2012. PMID: 22681673 Review.

5

Modifying the Poor Prognosis Associated with 18F-FDG-Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT).

Hofman MS, Michael M, Kashyap R, Hicks RJ. Hofman MS, et al. J Nucl Med. 2015 Jun;56(6):968-9. doi: 10.2967/jnumed.115.154500. Epub 2015 Mar 26. J Nucl Med. 2015. PMID: 25814516 Free article. No abstract available.

6

Reply: Modifying the Poor Prognosis Associated with 18F-FDG-Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT).

Garin E, Edeline J. Garin E, et al. J Nucl Med. 2015 Jun;56(6):969. doi: 10.2967/jnumed.115.158006. Epub 2015 Apr 23. J Nucl Med. 2015. PMID: 25908828 Free article. No abstract available.

7

Is 18F-Fluorodeoxyglucose the Tracer of Choice for Functional Imaging of Neuroendocrine Tumors Grade 3? A Case Report.

Lorusso M, Inzani F, Castaldi P, Menghi R, Schinzari G, Rindi G, Rufini V. Lorusso M, et al. Pancreas. 2018 Apr;47(4):e20-e22. doi: 10.1097/MPA.0000000000001012. Pancreas. 2018. PMID: 29521949 No abstract available.

8

[Contemporary nuclear medicine diagnostics of neuroendocrine tumors].

[No authors listed] [No authors listed] Srp Arh Celok Lek. 2015 Jan-Feb;143(1-2):108-15. doi: 10.2298/sarh1502108t. Srp Arh Celok Lek. 2015. PMID: 25845263 Free article. Serbian.

9

The Correlation Between [⁶⁸Ga]DOTATATE PET/CT and Cell Proliferation in Patients With GEP-NENs.

Yu J, Li N, Li J, Lu M, Leal JP, Tan H, Su H, Fan Y, Zhang Y, Zhao W, Zhu H, Pomper MG, Zhou Y, Yang Z. Yu J, et al. Mol Imaging Biol. 2019 Oct;21(5):984-990. doi: 10.1007/s11307-019-01328-3. Mol Imaging Biol. 2019. PMID: 30796708

10

Clinical and Prognostic Value of PET/CT Imaging with Combination of ⁶⁸Ga-DOTATATE and ¹⁸F-FDG in Gastroenteropancreatic Neuroendocrine Neoplasms.

Zhang P, Yu J, Li J, Shen L, Li N, Zhu H, Zhai S, Zhang Y, Yang Z, Lu M. Zhang P, et al. Contrast Media Mol Imaging. 2018 Feb 26;2018:2340389. doi: 10.1155/2018/2340389. eCollection 2018. Contrast Media Mol Imaging. 2018. PMID: 29681780 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed